IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection
about
Burden of pediatric hepatitis CPharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsRole of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control studyDistinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearancePrediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionDemographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese populationThe impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis CUsing decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment.The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia.IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.Host genomics and HCV treatment response.Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.Genetics of IL28B and HCV--response to infection and treatment.Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial.Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection.Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.Sustained viral response and hematological adverse events during chronic hepatitis C infection treatment.
P2860
Q27025476-BABBAAF3-4470-4ABD-AFAF-E6B1E339C121Q33404251-4E63BA1F-17F3-4921-A8AE-F6848AD8BD2AQ33408167-BF5E3810-FFAA-4003-BA34-2521A2AFAF19Q33559298-2EF01B71-9C39-4734-B4E4-8754454FBC55Q33807745-2115D3A4-5954-4412-B269-ECD059ADDD51Q33903850-FDAEA386-B061-42BD-8C4E-92807E4A7635Q34046758-63ED4887-6579-4729-BAA4-CAB3FFD78DD8Q34098886-3341872A-0583-4E2B-BDC6-D0427B5A69F8Q34429833-E24FC424-BFD3-4ED3-ADE4-2485F80F1BE0Q34464613-595ED5A7-C6F8-4316-875D-4DBE19C4B6F9Q34485088-1C3EB83D-877C-4454-A075-C66ACC16E108Q34604371-792CDEA8-F4AA-4488-9BC7-3285F4BAAABEQ34612816-A6CEFE66-FA75-464D-B739-9AAC65BE9C76Q34746864-F72B717E-63AD-41B0-9885-0A176A44CD7AQ35112286-44DD83EB-C071-4EC2-8473-AED45EF47CDFQ35122925-40AFE0C2-AD4C-466F-8787-149810E1F19CQ35131583-5CCEF97B-0AD9-4B5A-9D36-106E5B0B770CQ35226081-A5C2B216-9782-448F-ACC7-B1FB241471F4Q35591160-C03D3C24-71AB-4F23-AF30-34A7D725B68EQ35818383-C91249DD-5F79-4DF9-9E67-2A0AE8CDF6F4Q36044806-5D68EFC9-2D45-4D27-A9AE-49086CD75E11Q36080110-99E4B0BC-A95B-4E57-A1BC-0B2113A65679Q36183219-4ECEB704-AEC5-454E-9A88-245D8DEB7E78Q36208380-4DCF31E4-25DE-4BEB-BD15-F6A770CF5549Q36821268-159710C1-0990-4821-889E-BE631633E2A1Q37383288-3CD22DC3-6ED3-46C7-9CCE-B324DAFF33F7Q37428173-E0048D4E-0475-45F0-B039-6F3BE3DB157BQ37682146-03E2E901-101D-43AD-BE6C-A7EF38F9CCFFQ37932036-BF48B2EC-D0D1-4CFB-B599-292A65657816Q38011758-F904670E-A54F-4031-952C-FC7484743316Q38013941-62697384-D555-4EAE-8F44-D5F22C4CFC1DQ38136078-342B8E50-D033-41D1-BAF0-D6B8DBAFBB3BQ38477511-651229D0-5A1D-4D6E-A356-B80001099DEDQ40706760-13012DAE-F826-4F9B-A920-DBB49405C266Q42204985-03079A0E-C387-49D1-9767-A1F557A5178AQ42214593-54057F26-DF1D-4ACA-9DBC-3DA1DD0278F3Q42242611-05E69A9E-25C2-4863-B20E-E3AC6E5084DEQ42256205-74051D2C-8580-4D33-BBFB-BAF8A43F18AEQ42261289-6A7F84A6-046B-4002-91F3-54B1002888D2Q42554331-D9F14811-1864-46DB-A44A-757F70C7AC12
P2860
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@ast
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@en
type
label
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@ast
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@en
prefLabel
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@ast
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@en
P2093
P2860
P1433
P1476
IL28B SNP rs12979860 is a crit ...... s C virus genotype-1 infection
@en
P2093
Chang-Wen Huang
Chien-Hao Huang
Chun-Yen Lin
I-Shyan Sheen
Ji-Yih Chen
Su-Wei Chang
Tsung-Nan Lin
Wen-Juei Jeng
P2860
P304
P356
10.1371/JOURNAL.PONE.0018322
P407
P577
2011-03-30T00:00:00Z